Revvity, Inc. has announced its financial results for the third quarter of 2026, marking a pivotal moment for the company as it outlines plans to divest its Immunodiagnostics business in China. This strategic decision could significantly impact the laboratory analytical instruments industry, reshaping market dynamics and influencing competitors.

According to the filing dated November 3, 2026, Revvity reported its financial results for the quarter ending October 4, 2026. The company is in the process of finalizing a sale of its China Immunodiagnostics (China IDX) assets, which it expects to complete by the end of 2027. This sale is valued at up to $200 million, contingent upon certain conditions being met.

Background

Revvity, Inc., classified under the Standard Industrial Classification (SIC) code 3826, specializes in laboratory analytical instruments. The company trades on the New York Stock Exchange under the ticker symbol RVTY. Revvity has undergone several name changes in its history, previously known as PerkinElmer Inc. and EG&G Inc., with its current name adopted in 1999.

What the Filing Says

The filing reveals, "On November 3, 2026, Revvity, Inc. announced its financial results for the third quarter ended October 4, 2026." It also states, "Exhibit 99.2 to the Current Report on Form 8-K sets forth the unaudited pro forma condensed consolidated financial statements to present the pro forma financial position and results of operations of the Company and its Subsidiaries based upon historical financial information after giving effect to the probable sale of substantially all of the assets related to the Company’s Immunodiagnostics business in China."

Impact

This potential sale could affect various stakeholders, including investors, employees, and customers associated with the Immunodiagnostics segment. The divestiture may also influence competitors in the laboratory analytical instruments market, as Revvity's exit from this sector could create opportunities for others to capture market share.

What's Next

The filing does not say what happens next regarding the finalization of the sale or any subsequent strategic moves by Revvity.